Journal: Discover Oncology

Article Title: CRISPR/Cas technologies in pancreatic cancer research and therapeutics: recent advances and future outlook

doi: 10.1007/s12672-025-03383-5

Figure Lengend Snippet: Generation of pancreatic cancer models employing a range of CRISPR systems. Various CRISPR gene editing techniques are instrumental in generating GEMMs. Among them, CRISPR/Cas9 plays a pivotal role in the creation of transplantation models, either by modifying the genome of pancreatic cancer cells or by manipulating the immune system to facilitate PDX models. This system has also been widely applied in generating transgenic pancreatic cancer cell lines and genetically modified organoids, advancing research in cancer biology and therapeutic development

Article Snippet: 2 μg/ml puromycin at different time point (Day 15, 27, 31, 35) , HPAF-II, AsPC-1, PaTu8988S , Knockout , Toronto KnockOut (TKO) CRISPR Library (addgene No. 1000000069) , Wnt pathway genes, FZD5 , CRISPR knockout, Antibody-mediated inhibition , -Reduced proliferation , [ ] .

Techniques: CRISPR, Transplantation Assay, Transgenic Assay, Genetically Modified

Journal: Discover Oncology

Article Title: CRISPR/Cas technologies in pancreatic cancer research and therapeutics: recent advances and future outlook

doi: 10.1007/s12672-025-03383-5

Figure Lengend Snippet: Pooled CRISPR screening approaches in different experimental conditions. In direct in vivo screening, CRISPR is delivered into living organisms (e.g., mice) to induce genetic modifications in their natural biological context. In indirect in vivo screening, CRISPR is applied to cell lines or organoids derived from the in vivo model, which are then reintroduced into the organism, allowing for controlled exploration of genetic modifications. In vitro CRISPR screening is conducted in cultured cells for high-throughput gene editing and analysis of specific genetic targets. Sequencing technologies, such as NGS, are then used to identify novel oncogenes and druggable targets, providing insights into gene functions and the impact of specific genetic changes in isolated cells

Article Snippet: 2 μg/ml puromycin at different time point (Day 15, 27, 31, 35) , HPAF-II, AsPC-1, PaTu8988S , Knockout , Toronto KnockOut (TKO) CRISPR Library (addgene No. 1000000069) , Wnt pathway genes, FZD5 , CRISPR knockout, Antibody-mediated inhibition , -Reduced proliferation , [ ] .

Techniques: CRISPR, In Vivo, Derivative Assay, In Vitro, Cell Culture, High Throughput Screening Assay, Sequencing, Isolation

Journal: Discover Oncology

Article Title: CRISPR/Cas technologies in pancreatic cancer research and therapeutics: recent advances and future outlook

doi: 10.1007/s12672-025-03383-5

Figure Lengend Snippet: Therapeutic applications of CRISPR-driven gene editing. Through the targeted modification of key factors involved in the pathogenesis of pancreatic cancer, CRISPR systems, employing diverse mechanisms, offer promising prospects for advancing therapeutic strategies in the treatment of pancreatic cancer. PC pancreatic cancer

Article Snippet: 2 μg/ml puromycin at different time point (Day 15, 27, 31, 35) , HPAF-II, AsPC-1, PaTu8988S , Knockout , Toronto KnockOut (TKO) CRISPR Library (addgene No. 1000000069) , Wnt pathway genes, FZD5 , CRISPR knockout, Antibody-mediated inhibition , -Reduced proliferation , [ ] .

Techniques: CRISPR, Modification